Preliminary findings indicate that dysregulation of NF-κβ/ TLR-4 and SERCA/ Ca2 + pathways are involved in the pathogenesis of T2DM, and these pathogenic hotspots can be effectively targeted by therapeutically active compounds present in AGE [29, 31, 32]. The gene discussed is TLR4; the disease is type 2 diabetes mellitus.